- Marinus Pharmaceuticals press release (NASDAQ:MRNS): Q2 GAAP EPS of -$1.06 misses by $0.37.
- Revenue of $1.8M (-5.8% Y/Y) misses by $0.51M.
- GUIDANCE
- For the fiscal year 2022, the Company expects BARDA revenues in the range of $7 to $10 million and total GAAP operating expenses, inclusive of G&A and R&D, to be in the range of $150 to $155 million, of which the Company expects stock-based compensation to be approximately $15 million.
- Previously, total GAAP operating expenses were expected in the range of $152 to $157 million and the stock-based compensation estimate was approximately $17 million. BARDA revenue estimates remain unchanged from the prior guidance.